Previous studies established some Ti compounds as having marked activity against tumors of the gastrointestinal tract and lack of side effects common to widely used cytostatic agents. We describe pertinent structural features of known antitumor Ti agents and other potentially active compounds. Particularly noteworthy features are that Ti-O bonds are short and Ti-O-Ti bond angles are large, demonstrating that in these compounds the O binding has high s-character approaching sp hybridization.
Since 13-diketone asymmetry is an essential feature for high activity in budotitane and related compounds /2/, we are studying closely related Ti derivatives with 4-acyl-5-pyrazolones 6 as ligands, see Figure 6 . These are asymmetric 13-diketones having 3 possible substitution options.
A compound showing in vivo antitumor activity (T/C about 300%) against TA-3 (mouse mammary adenocarcinoma) in AJ mice, slightly lower than that found for budotitane against other tumors/2/, was synthesized by our group /11/. It is a bis(4-acyl-5-pyrazolonato)titanium(IV) tetranuclear cyclic species, [(Q)_Ti(. DFT structure of the (QT)2TiCI2 conformer CIS2. [27] . 
